C
085660
vs
K
KOSPI 200
Over the past 12 months, Chabiotech Co Ltd has underperformed KOSPI 200, delivering a return of -27% compared to KOSPI 200's +149% growth.
Stocks Performance
085660 vs KOSPI 200
Performance Gap
085660 vs KOSPI 200
Performance By Year
085660 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Chabiotech Co Ltd
Glance View
Chabiotech Co Ltd develops and sells molecular diagnostic products used to detect infectious diseases and other medical conditions. Its main products are test kits, reagents, and related lab consumables that hospitals, clinics, laboratories, and public health organizations use to identify pathogens and support diagnosis. The company sits in the medical testing supply chain, turning biological samples into lab results that help doctors make decisions. The company makes money by selling these diagnostic kits and reagents to customers in South Korea and overseas, either directly or through distributors. Its business depends on repeat demand because many test kits and chemicals are used up with each round of testing. That gives Chabiotech a recurring-revenue style model tied to ongoing laboratory use rather than one-time equipment sales. What makes the business distinct is its focus on specialized molecular testing, especially products built around DNA- and RNA-based detection methods. This puts it in a technical part of healthcare where accuracy, speed, and regulatory approval matter a lot. For investors, the key idea is that Chabiotech is not a broad healthcare company; it is a niche diagnostics supplier that earns from the sale of lab tests and the materials needed to run them.
